



(51) International Patent Classification:

C07D 307/81 (2006.01) A61K 31/343 (2006.01)

(21) International Application Number:

PCT/US2024/030109

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/503,157	18 May 2023 (18.05.2023)	US
63/564,028	12 March 2024 (12.03.2024)	US

(71) Applicant: **ENVEDA THERAPEUTICS, INC.** [US/US];
5700 Flatiron Parkway, Boulder, Colorado 80301 (US).(72) Inventors: **RAMDAS, Vidya**; c/o Enveda Therapeutics,
India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, Visakhapatnam AP 530003 (IN). **JADHAVA, Prabhakar Kondaji**; c/o Enveda Therapeutics,
Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **WALKE, Deepak Sahebrao**; c/o Enveda Therapeutics,
India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, Visakhapatnam AP 530003 (IN). **KARATHANASIS, Sotirios K**; c/o Enveda Therapeutics,
Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **NORMAN, Bryan Hurst**; c/o Enveda Therapeutics,



tics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **YU, Marvin**; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **HIGHTOWER, Kendra E.**; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **MEMON, Tosifa**; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US).

(74) Agent: **CHOI, Anita** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: G-PROTEIN COUPLED RECEPTOR ANTAGONIST

**FIG. 1**

(57) **Abstract:** The present disclosure relates generally to compounds, compositions, and methods for treating a variety of diseases and conditions using a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, or derivative thereof.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*